List of Excipients in Branded Drug ANALPRAM HC

Generic Drugs Containing ANALPRAM HC

Company	Ingredient	NDC	Excipient
Sebela Pharmaceuticals Inc	hydrocortisone acetate and pramoxine hydrochloride	54766-778	CETYL ALCOHOL
Sebela Pharmaceuticals Inc	hydrocortisone acetate and pramoxine hydrochloride	54766-778	ISOPROPYL PALMITATE
Sebela Pharmaceuticals Inc	hydrocortisone acetate and pramoxine hydrochloride	54766-778	POLYOXYL 40 STEARATE
Sebela Pharmaceuticals Inc	hydrocortisone acetate and pramoxine hydrochloride	54766-778	POTASSIUM SORBATE
Sebela Pharmaceuticals Inc	hydrocortisone acetate and pramoxine hydrochloride	54766-778	PROPYLENE GLYCOL
Sebela Pharmaceuticals Inc	hydrocortisone acetate and pramoxine hydrochloride	54766-778	SORBIC ACID
Sebela Pharmaceuticals Inc	hydrocortisone acetate and pramoxine hydrochloride	54766-778	STEARIC ACID

What are the Most Frequently-Used Excipients in ANALPRAM HC?

# Of NDCs	Excipient
5	CETYL ALCOHOL
2	DIISOPROPYL ADIPATE
2	DIMETHICONE
2	GLYCERIN
2	HYDROGENATED COCONUT OIL
3	ISOPROPYL PALMITATE
2	LANOLIN

Last updated: August 4, 2026

Analpram HC is a prescription anorectal cream combining hydrocortisone acetate 2.5% with pramoxine hydrochloride 1%. Its commercial opportunity is primarily a lower-cost generic cream, followed by differentiated products using lower-irritancy, preservative-free, metered-dose, single-use, or alternative semisolid delivery systems. The core regulatory challenge is demonstrating pharmaceutical equivalence and comparable performance for a locally acting topical product, not establishing systemic bioequivalence alone.

Analpram HC Excipient Strategy and Commercial Opportunities

What is Analpram HC and how does its formulation work?

Analpram HC contains two active pharmaceutical ingredients:

Component	Strength	Function
Hydrocortisone acetate	2.5%	Topical corticosteroid that reduces inflammation and itching
Pramoxine hydrochloride	1%	Local anesthetic that reduces anorectal pain and discomfort

The product is indicated for temporary relief of itching, burning, and discomfort associated with hemorrhoids and other anorectal disorders. The cream is intended for external and intrarectal use with an applicator. The U.S. product is prescription-only because it contains hydrocortisone acetate at 2.5%, above the concentration generally associated with over-the-counter hydrocortisone anorectal products. [1,2]

The formulation must deliver both actives to diseased anorectal tissue while maintaining:

• Physical and chemical stability in a water-containing cream.
• Uniform distribution of hydrocortisone acetate, which has limited aqueous solubility.
• Adequate dissolution and release of pramoxine hydrochloride.
• Acceptable spreading, washability, adhesion, and patient comfort.
• Microbiological control during repeated use.
• Compatibility with the tube, applicator, and closure system.

What excipients are used in Analpram HC?

Public product labeling identifies a conventional oil-in-water cream system containing fatty alcohols, emulsifiers, humectants, preservatives, hydrocarbons, and purified water. The listed inactive ingredients include the following excipient classes. [1]

Excipient or class	Likely formulation role	Commercial relevance
Cetyl alcohol and stearyl alcohol	Consistency agents, emulsion stabilizers, emollients	Influence viscosity, spreadability, and sensory profile
Glyceryl monostearate	Emulsifier and texture modifier	Supports cream structure
Polysorbate 60 and sorbitan monostearate	Nonionic emulsifier system	Helps stabilize the oil-water interface
Mineral oil and white petrolatum	Occlusive emollients	Improve lubrication and barrier properties
Propylene glycol	Humectant and solvent	Can improve wetting and solubilization but may irritate some users
Sodium lauryl sulfate	Surfactant	Supports emulsification but can increase irritation potential
Methylparaben and propylparaben	Preservatives	Protect the multidose aqueous cream from microbial growth
Purified water	Continuous aqueous phase	Vehicle for the cream

The specific quantitative composition is not generally disclosed in the commercial label. That limits direct replication based solely on public information. A generic manufacturer would need to develop a composition that meets the relevant pharmaceutical equivalence, performance, stability, and microbiological requirements.

What excipient strategy is best for a generic Analpram HC cream?

A conventional Q1/Q2-matched cream is the lowest-risk development path. Q1 sameness means using the same inactive ingredients. Q2 sameness means using the same ingredients in the same concentrations, subject to applicable FDA tolerances and product-specific requirements. For a locally acting topical product, matching the reference formulation can simplify the regulatory argument, but it does not eliminate the need for comparative performance testing.

Recommended base strategy

The most defensible initial formulation would retain:

1. A nonionic emulsifier system.
2. A petrolatum and mineral-oil emollient phase.
3. Fatty alcohols for viscosity and structure.
4. A preserved aqueous phase.
5. A rheology profile close to the reference product.
6. The same active concentrations and route of administration.

This approach reduces risks involving phase separation, altered drug release, poor applicator delivery, and unexpected local irritation.

Hydrocortisone acetate considerations

Hydrocortisone acetate is lipophilic and poorly soluble in water. It may be present as suspended particles or partially dissolved in the internal phase, depending on the formulation. Particle size, crystal form, wetting, and dispersion quality can materially affect:

• Content uniformity.
• In vitro release.
• Local deposition.
• Stability.
• Sedimentation or creaming.
• Batch-to-batch reproducibility.

A developer should control hydrocortisone acetate particle-size distribution and assess polymorphic behavior. Replacing the reference surfactant system or reducing the oil phase may change drug release even when the active concentration remains unchanged.

Pramoxine hydrochloride considerations

Pramoxine hydrochloride is more water-compatible than hydrocortisone acetate. Its distribution within the aqueous phase depends on pH, ionic strength, preservative concentration, and interactions with surfactants. The formulation should control pH within a range that supports:

• Pramoxine chemical stability.
• Preservative efficacy.
• Skin and mucosal tolerability.
• Compatibility with the emulsion system.

The pH should not be selected solely for maximum pramoxine solubility. An anorectal product with excessive acidity, alkalinity, or surfactant activity may generate poor tolerability and lower repeat use.

Which excipient changes create the strongest commercial differentiation?

The most practical opportunities are incremental formulation improvements that preserve the cream dosage form and therapeutic combination.

Preservative-free packaging

A preservative-free Analpram HC alternative could use:

• Single-use sachets.
• Unit-dose applicators.
• Airless dispensers.
• Specialized multidose systems that limit microbial ingress.

The opportunity is commercially attractive because anorectal products are used on irritated tissue, where preservatives and surfactants may contribute to discomfort. The tradeoff is higher packaging cost, more complex filling operations, and the need to validate container-closure integrity and in-use microbiological performance.

A preservative-free product in conventional multidose packaging would face a substantial contamination risk. Removing methylparaben and propylparaben without changing the package would not be a credible strategy.

Lower-irritancy surfactant system

Sodium lauryl sulfate can improve emulsification but is associated with irritation concerns in sensitive or damaged tissue. A reformulation using milder nonionic surfactants could support a premium positioning.

Potential substitutes include:

• Polysorbate-based systems.
• Sorbitan ester combinations.
• Poloxamers.
• Glyceryl-based self-emulsifying systems.
• Phospholipid or lecithin-derived emulsifiers.

The principal regulatory risk is altered drug release. The formulation must demonstrate that the replacement system does not change hydrocortisone acetate particle dispersion, pramoxine release, viscosity, or tissue deposition.

Reduced propylene glycol formulation

Propylene glycol is useful as a humectant and solvent but can cause stinging or irritation in some patients, especially on compromised skin. A lower-propylene-glycol or propylene-glycol-free product could target patients who discontinue treatment because of burning.

Possible replacements include glycerol, polyethylene glycol grades, or alternative aqueous-phase modifiers. Each option can change water activity, preservative efficacy, viscosity, and pramoxine solubilization.

Improved rheology and adhesion

Anorectal creams must spread easily but remain at the application site. A formulation that is too thin may leak or require repeated dosing. A formulation that is too thick may be difficult to apply through the applicator.

Rheology can be adjusted through:

• Fatty alcohol concentration.
• Petrolatum-to-mineral-oil ratio.
• Emulsifier balance.
• Polymer thickeners.
• Structured lipid systems.

Polymer additions create a potential differentiation point but may complicate Q1/Q2 sameness and change the drug-release profile. A controlled yield stress and shear-thinning profile may improve patient handling without requiring a new dosage form.

What formulations are protected or commercially available for Analpram HC?

The principal public product is the hydrocortisone acetate 2.5% and pramoxine hydrochloride 1% cream. Related anorectal products include:

• Hydrocortisone-only creams.
• Pramoxine-only creams.
• Lower-strength over-the-counter hydrocortisone products.
• Combination products containing protectants such as zinc oxide, petrolatum, or mineral oil.
• Suppositories and ointments with different active ingredients.

A formulation using the same active ingredients in a materially different dosage form, such as foam, suppository, gel, spray, or wipe, may require a different regulatory strategy. It may not qualify as a straightforward ANDA because dosage-form changes can affect local delivery, labeling, clinical performance, and product characterization.

The strongest commercial white space is therefore a better cream or a closely related semisolid product, rather than a radically different delivery system.

What is the FDA regulatory status of Analpram HC?

Analpram HC is a prescription topical anorectal product. A generic applicant would generally evaluate the product under the abbreviated new drug application pathway if an appropriate reference listed drug is identified and the proposed product satisfies the applicable sameness and bioequivalence requirements. [2,3]

For locally acting topical products, FDA may expect a package of evidence that includes:

• Active ingredient identity and strength.
• Dosage-form and route sameness.
• Q1/Q2 comparison where applicable.
• Comparative physicochemical characterization.
• In vitro release testing.
• In vitro permeation or other performance testing where relevant.
• Microbiological limits and preservative effectiveness.
• Stability data.
• Container-closure compatibility.
• Comparative product quality attributes.

FDA's guidance for topical dermatological products emphasizes comparative characterization because systemic pharmacokinetic testing may not adequately measure local product performance. [4]

A reformulated product with a new excipient system may still qualify for an ANDA if it meets the relevant requirements, but the regulatory burden rises as the composition, dosage form, device, or release behavior diverges from the reference.

When does Analpram HC lose exclusivity and what patent barriers exist?

The product is an older topical combination, and its principal commercial barrier is likely formulation execution rather than remaining brand exclusivity. The commercial label does not itself establish an enforceable patent term, patent number, or exclusivity period. Patent and exclusivity conclusions should be based on the current FDA Orange Book record and relevant patent databases. [2,5]

For an abbreviated application, the key patent questions are:

Issue	Relevance
Listed patents	Determine whether a Paragraph IV certification is required
Expired composition or formulation patents	May permit immediate approval if no other barrier remains
Method-of-use patents	Could affect labeling and launch strategy
Pediatric exclusivity	Can add six months to qualifying listed protections
Regulatory exclusivity	Older products generally have limited remaining exclusivity
Patent litigation	A timely Paragraph IV suit can trigger a 30-month stay

If no unexpired relevant patent remains, a generic applicant could seek approval without a Paragraph IV litigation event. If a patent is listed, the applicant could certify Paragraph III, Paragraph IV, or another applicable statutory position. Under the Hatch-Waxman framework, a timely patent-infringement action after a Paragraph IV notice can trigger a statutory stay of FDA approval for up to 30 months, subject to court developments. [6]

Which companies are challenging Analpram HC?

Publicly visible competition is more likely to come from manufacturers of generic hydrocortisone-pramoxine creams and adjacent anorectal products than from biosimilar developers. Analpram HC is a small-molecule topical product and has no biosimilar pathway.

Competitive activity should be assessed across four groups:

1. Generic manufacturers seeking the same hydrocortisone acetate/pramoxine hydrochloride combination.
2. Manufacturers of hydrocortisone-only anorectal products.
3. Manufacturers of pramoxine-only products.
4. Branded consumer-health companies selling lower-strength or protectant-based alternatives.

A Paragraph IV challenge would be relevant only if an unexpired listed patent covers the reference product or a claimed method of use. A generic applicant may also pursue a non-infringing formulation that avoids a formulation patent while maintaining pharmaceutical equivalence.

How strong is the Analpram HC patent estate?

The likely patent strength is moderate to weak for the basic active combination because hydrocortisone and pramoxine are established ingredients and the product is an older conventional cream. The more defensible areas are:

• Specific excipient ratios.
• Particle-size-controlled hydrocortisone acetate.
• Preservative-free packaging.
• Applicator and container-closure systems.
• Improved stability.
• Defined rheological parameters.
• Novel foam, gel, or unit-dose delivery systems.
• Manufacturing processes that improve content uniformity.

A new patent strategy should focus on measurable formulation attributes rather than broad claims to the known active ingredients. Claims directed only to combining hydrocortisone acetate and pramoxine in a cream would face substantial prior-art risk.

What manufacturing and intellectual-property barriers affect generic entry?

Manufacturing barriers are manageable but technically meaningful. The main risks are:

• Inadequate hydrocortisone acetate dispersion.
• Nonuniform active distribution during scale-up.
• Emulsion instability.
• Preservative failure.
• Applicator blockage.
• Tube fill-weight variation.
• Long-term viscosity drift.
• Interaction between the cream and packaging.
• Inconsistent in vitro release.

A robust process would control the order of phase addition, homogenization energy, temperature history, cooling profile, active incorporation, deaeration, and filling conditions. Hydrocortisone acetate should be added under conditions that prevent agglomeration and maintain the target particle-size distribution.

The most valuable manufacturing know-how may be trade-secret process control rather than patent protection. This includes dispersion conditions, shear history, cooling rate, and hold-time limits.

What are the commercial opportunities and revenue scenarios?

Analpram HC is a focused product with a limited patient population compared with mass-market dermatology products. Its commercial value comes from repeat use, prescription reimbursement, physician familiarity, and the lack of many differentiated combination products.

Opportunity	Value proposition	Development risk	Commercial potential
Standard generic cream	Lower acquisition cost	Low to moderate	High relative to development cost
Preservative-free unit-dose cream	Lower exposure to preservatives; improved hygiene	Moderate	Premium niche
Low-irritancy cream	Better tolerability on damaged tissue	Moderate	Moderate
Metered-dose applicator	Dose consistency and cleaner use	Moderate to high	Moderate
Lower-mess ointment or cream	Improved adherence	Moderate	Moderate
Foam or gel	Distinct sensory profile and delivery	High	Uncertain but potentially differentiated
OTC-oriented lower-strength product	Larger consumer market	High because of monograph and labeling requirements	Potentially high

The standard generic has the best risk-adjusted profile. A differentiated product should be developed only if the sponsor has a defensible package, device, manufacturing, or clinical-use advantage.

How does Analpram HC compare with competing anorectal products?

Product category	Anti-inflammatory effect	Local anesthetic effect	Typical regulatory position	Main weakness
Analpram HC-type combination	Hydrocortisone acetate 2.5%	Pramoxine 1%	Prescription	Higher regulatory and reimbursement requirements
Hydrocortisone-only product	Yes	No	OTC at lower strengths; prescription at higher strengths	Does not directly address pain
Pramoxine-only product	No	Yes	Often OTC depending on product and labeling	Does not treat inflammation
Protectant-only product	No direct corticosteroid or anesthetic action	Usually limited	OTC	Lower pharmacologic intensity
Suppository product	Depends on active ingredients	Depends on active ingredients	Product-specific	Different delivery and patient preference

Analpram HC has a clear functional advantage over single-active products because it addresses inflammation and discomfort. Its disadvantages are prescription access, possible excipient-related irritation, and the need for an applicator in intrarectal use.

What patent litigation and settlement issues should investors monitor?

Relevant litigation indicators include:

• A Paragraph IV notice involving a listed formulation or method patent.
• A 30-month stay under Hatch-Waxman.
• A first-filer designation and 180-day generic exclusivity.
• A settlement restricting generic launch.
• A covenant not to sue covering a specific formulation.
• A patent-license agreement involving an excipient, package, or delivery device.

For an older topical product, settlement risk may be lower than for high-revenue oral or injectable products. The principal commercial risk is often rapid multi-source generic entry once approval becomes available. A first approved generic may obtain temporary share advantages, but those advantages can erode quickly if several manufacturers launch.

Key Takeaways

• Analpram HC combines hydrocortisone acetate 2.5% and pramoxine hydrochloride 1% in a conventional preserved cream.
• The highest-probability opportunity is a Q1/Q2-oriented generic cream with controlled hydrocortisone acetate dispersion and equivalent in vitro performance.
• Preservative-free unit-dose packaging is the clearest premium formulation opportunity.
• Lower-irritancy excipient systems could differentiate the product, but surfactant and solvent changes require close release, stability, and tolerability evaluation.
• No biosimilar pathway applies because Analpram HC is a small-molecule topical product.
• Patent risk should be assessed through current Orange Book listings and prosecution records, not through the product label alone.
• Manufacturing know-how involving dispersion, emulsification, cooling, and filling may create a stronger practical barrier than broad composition patents.
• A foam, gel, or suppository would have greater differentiation but also higher regulatory and clinical-performance risk.

FAQs About Analpram HC Excipient and Market Strategy

Can a generic Analpram HC product remove parabens?

Yes, but the change can affect ANDA strategy, preservative efficacy, stability, and pharmaceutical equivalence. Preservative removal is most credible when paired with a unit-dose or contamination-limiting package.

Is pramoxine hydrochloride compatible with hydrocortisone acetate?

Yes, the actives can be formulated together in a cream. Compatibility depends on pH, water activity, surfactant selection, particle dispersion, preservative system, and storage conditions.

Could Analpram HC be developed as an OTC product?

A lower-strength product may be evaluated under applicable OTC anorectal monograph requirements, but the 2.5% hydrocortisone acetate prescription product should not be assumed to qualify for OTC marketing without a separate regulatory assessment.

What excipient has the greatest effect on hydrocortisone acetate release?

The oil phase, emulsifier balance, and active-particle wetting system usually have the greatest effect because hydrocortisone acetate is relatively lipophilic and poorly water-soluble.

Is a metered-dose Analpram HC applicator patentable?

Potentially. Patentability would depend on novelty and non-obviousness of the applicator structure, dose-control mechanism, contamination barrier, or interaction with the cream formulation. Broad claims to a generic applicator are unlikely to provide strong protection.

References

1. DailyMed. (n.d.). Analpram-HC 2.5%: Hydrocortisone acetate and pramoxine hydrochloride cream, label. U.S. National Library of Medicine.

2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugsatfda

4. U.S. Food and Drug Administration. (2022). Guidance for industry: In vitro release test studies for topical drug products submitted in ANDAs. Center for Drug Evaluation and Research.

5. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/

6. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j); 35 U.S.C. § 271(e).